Capricor Therapeutics Inc.’s recently made public that its Former CBO Avat Xavier unloaded Company’s shares for reported $64258.0 on Apr 17. In the deal valued at $4.35 per share,14,772 shares were sold. As a result of this transaction, Avat Xavier now holds 0 shares worth roughly $ 0.0.
Then, Avat Xavier sold 3,000 shares, generating $12,180 in total proceeds. Upon selling the shares at $4.06, the FORMER CHIEF BUSINESS OFFICER now owns 0 shares.
Ladenburg Thalmann initiated its Capricor Therapeutics Inc. [CAPR] rating to a Buy in a research note published on Friday, October 26, 2022; the price target was $15. PT values the company’s stock at a premium of 55.93 to its Friday closing price.
Price Performance Review of CAPR
On Friday, Capricor Therapeutics Inc. [NASDAQ:CAPR] saw its stock jump 2.01% to $6.61. On the same session, the stock had its day’s lowest price of $6.46, but rose to a high of $6.68. Over the last five days, the stock has lost -14.93%. Capricor Therapeutics Inc. shares have risen nearly 71.24% since the year began. Nevertheless, the stocks have risen 13.57% over the past one year. While a 52-week high of $8.22 was reached on 08/28/23, a 52-week low of $3.30 was recorded on 01/03/23. SMA at 50 days reached $5.42, while 200 days put it at $4.53. A total of 96127.0 shares were traded, compared to the trading of 0.22 million shares in the previous session.
Levels Of Support And Resistance For CAPR Stock
The 24-hour chart illustrates a support level at 6.49, which if violated will result in even more drops to 6.36. On the upside, there is a resistance level at 6.71. A further resistance level may holdings at 6.80. The Relative Strength Index (RSI) on the 14-day chart is 53.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.54, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.24%. Stochastics %K at 30.21% indicates the stock is a holding.
How much short interest is there in Capricor Therapeutics Inc.?
A steep rise in short interest was recorded in Capricor Therapeutics Inc. stocks on Aug 14, 2023, growing by 41020.0 shares to a total of 0.32 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.27 million shares. There was a rise of 13.0%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 1.26% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.97.
Capricor Therapeutics Inc. [CAPR] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 1,138,223 shares, or roughly 4.50% of the outstanding CAPR shares. In other words, the investor’s shares have fallen by -4,625 from its previous 13-F filing of 1142848.0. Additionally, BlackRock Fund Advisors increased 4.23% of its stake after which the total value it holdings stand at $1,789,146, while Geode Capital Management LLC added 28.76% of its stake to hold $1.31 million in the firm. Over the last quarter, Northern Trust Investments, Inc. sold -467 shares of Capricor Therapeutics Inc., while SSgA Funds Management, Inc. sold 0 shares. At present, LPL Financial LLC is holding 78,436 shares valued at $0.35 million. Newton Investment Management Nort owned 60,440 shares of the company at the time of its most recent 13F filing, worth $0.27 million.
According to FactSet, Capricor Therapeutics Inc.’s share price will average $15.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 131.48 percent from its previous closing price of $6.48. Analysts expect Capricor Therapeutics Inc. stock to reach the higher price of $18.00, while the lowest price estimate is $12.00. However, 3 analysts have rated CAPR stock as a Buy in their predictions for 2023.